Literature DB >> 28779635

Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: A literature-based critical review.

Abrahim Al-Mamgani1, Erik van Werkhoven2, Arash Navran3, Baris Karakullukcu4, Olga Hamming-Vrieze3, Melanie Machiels5, Lilly-Ann van der Velden4, Wouter V Vogel6, W Martin Klop4.   

Abstract

BACKGROUND: The head and neck region has rich regional lymphatic network, with a theoretical risk on contralateral metastasis from oropharyngeal cancer (OPC). There is a long-standing convention to irradiate the great majority of these tumors electively to both sides of the neck to reduce the risk of contralateral regional failure (cRF), but this can induce significant toxicity. We aimed to identify patient groups where elective contralateral irradiation may safely be omitted.
METHODS: PubMed and EMBASE were searched for original full-text articles in English with a combination of search terms related to the end points: cRF in OPC primarily treated by radiotherapy only to the ipsilateral neck and identifying predictive factors for increased incidence of cRF. The data from the identified studies were pooled, the incidence of cRF was calculated and the correlation with different predictive factors was investigated.
RESULTS: Eleven full-text articles met the inclusion criteria. In these studies, 1116 patients were treated to the ipsilateral neck alone. The mean incidence of cRF was 2.42% (range 0-5.9%, 95% CI 1.6-3.5%). The incidence of cRF correlated only with T-stage (p=0.008), and involvement of midline (p=0.001). However, the significant correlation with T-stage can be explained by the very low incidence of cRF among T1 (0.77%), and disappeared when the incidence of cRF was compared between T2, T3,and T4 (p=0.344).
CONCLUSION: The incidence of cRF in patients with OPC is very low, with involvement of midline providing the most significant prognosticator. These results call for trials on unilateral elective irradiation in selected groups.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Contralateral failure; Contralateral regional recurrence; Elective irradiation; Oropharyngeal cancer; Unilateral neck irradiation

Mesh:

Year:  2017        PMID: 28779635     DOI: 10.1016/j.ctrv.2017.07.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  12 in total

1.  SPECT/CT-guided lymph drainage mapping for the planning of unilateral elective nodal irradiation in head and neck squamous cell carcinoma.

Authors:  Pieter D de Veij Mestdagh; Marcel C J Jonker; Wouter V Vogel; Willem H Schreuder; Maarten L Donswijk; W Martin C Klop; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-28       Impact factor: 2.503

2.  [Omission of postoperative radiation to pathologically tumor-free cervical lymphatic pathway: long-term results of a prospective phase II study].

Authors:  Erik Haehl; Nils H Nicolay
Journal:  Strahlenther Onkol       Date:  2020-01       Impact factor: 3.621

Review 3.  Current Standards for Organ Preservation in Locoregionally Advanced Non-nasopharyngeal Head and Neck Cancer and Evolving Strategies for Favorable-Risk and Platinum-Ineligible Populations.

Authors:  Susan Y Wu; Sue S Yom
Journal:  Curr Treat Options Oncol       Date:  2019-12-04

4.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

5.  Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy.

Authors:  Nicolette Taku; Gregory Chronowski; G Brandon Gunn; William H Morrison; Neil D Gross; Amy C Moreno; Renata Ferrarotto; Steven J Frank; C David Fuller; Ryan P Goepfert; Jack Phan; Stephen Y Lai; Jay P Reddy; David I Rosenthal; Adam S Garden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-05-02       Impact factor: 8.013

6.  Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma.

Authors:  Lachlan McDowell; Georgina Casswell; Mathias Bressel; Karla Gough; Allison Drosdowsky; Andrew Coleman; Sudi Shrestha; Ieta D'Costa; Tsien Fua; Albert Tiong; Chen Liu; Sweet Ping Ng; Benjamin Solomon; Danny Rischin
Journal:  Clin Transl Radiat Oncol       Date:  2020-01-30

7.  Low risk of contralateral lymph node recurrence in lateralized head and neck carcinoma after postoperative ipsilateral radiotherapy.

Authors:  Mirja M Wirtz; Susanne Temming; Martin Kocher; Sabine Kunze; Robert Semrau
Journal:  Strahlenther Onkol       Date:  2019-12-12       Impact factor: 3.621

Review 8.  Ipsilateral radiation for squamous cell carcinoma of the tonsil: American Radium Society appropriate use criteria executive summary.

Authors:  C Jillian Tsai; Thomas J Galloway; Danielle N Margalit; Richard L Bakst; Beth M Beadle; Jonathan J Beitler; Steven Chang; Allen Chen; Jay Cooper; Shlomo A Koyfman; John A Ridge; Jared Robbins; Minh Tam Truong; Sue S Yom; Farzan Siddiqui
Journal:  Head Neck       Date:  2020-10-17       Impact factor: 3.821

9.  Incidence of contralateral regional failure in the electively irradiated contralateral neck of patients with head and neck squamous cell carcinoma.

Authors:  Pieter D de Veij Mestdagh; Eric van Werkhoven; Arash Navran; Jan Paul de Boer; Willem H Schreuder; Wouter V Vogel; Abrahim Al-Mamgani
Journal:  Clin Transl Radiat Oncol       Date:  2019-04-19

10.  Long-term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study.

Authors:  Shengjin Dou; Rongrong Li; Lin Zhang; Zhuoying Wang; Li Xie; Chenping Zhang; Guopei Zhu
Journal:  Cancer Med       Date:  2020-01-17       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.